Pauling.AI

Pauling.AI is the first fully autonomous drug discovery platform, designed to take researchers from a research idea to validated drug molecules in days rather than years. Built for medicinal chemists and life sciences researchers who lack computational chemistry expertise, Pauling.AI eliminates the complexity of traditional in silico workflows by deploying an intelligent AI agent that orchestrates the entire drug discovery pipeline — from target input to ranked, validated hits — without requiring users to manage software, convert files, or configure parameters manually.

Traditional drug discovery is costly and slow, with an average timeline of 10–15 years per drug, costs exceeding $2.6 billion per approval, and a 90% failure rate. Most existing AI tools are either single-purpose models or complex platforms that demand deep computational expertise. Pauling.AI addresses this gap by combining AI agents, enterprise-scale cloud infrastructure, and the latest AI models — including Boltz and DiffDock — with established computational chemistry methods, all automated within a single unified system.

End-to-End Autonomous Workflow

• Tell the AI your target: Provide a protein target (e.g., a PDB code such as "6VC8") through a conversational interface — no computational chemistry knowledge required.
• AI agent designs the workflow: The intelligent agent automatically selects optimal protocols, determines simulation conditions, and configures the complete computational pipeline.
• Execute at enterprise scale: Process millions of compounds in parallel using cloud infrastructure with fault-tolerant, restartable pipelines for reliable execution.
• Quality control and validation: Automated quality checks using MolProbity analysis and PoseBusters validation ensure only high-quality, drug-like molecules advance to final ranking.
• ADMET and safety profiling: Predict 80+ drug properties — including absorption, metabolism, toxicity, and off-target effects — before synthesis, reducing costly late-stage failures.
• Molecular dynamics validation: Advanced molecular dynamics (MD) simulations validate top hits with binding affinity estimation and stability analysis, providing confidence in selected compounds.

15+ Integrated Computational Pipelines

• Receptor preparation and protonation
• Large-scale, state-of-the-art molecular docking
• Integration of the latest AI models including Boltz and DiffDock
• Molecular dynamics simulations and binding affinity estimation
• ADMET property prediction across 80+ endpoints
• Automated quality control and validation throughout the pipeline

Enterprise Cloud Infrastructure

• Capacity to process millions of compounds in parallel
• Auto-scaling cloud resources to meet research demands
• Fault-tolerant execution with restartable job management
• Secure data handling throughout all stages of the workflow

Multi-LLM AI Agent Capabilities

• Conversational interface for intuitive target and project input
• Expert-level protocol selection guided by biological context
• pH optimization tailored to specific targets
• Multi-model AI support with continuous learning
• Autonomous adaptation of simulation conditions based on molecular properties

Complete Automation — No Manual Overhead

• No uploading and downloading data — all work happens directly in the cloud with seamless data flow between computational tools.
• No converting files — the platform automatically handles all format conversions between different software packages.
• No manual parameter setting — AI agents optimize simulation conditions based on the specific target and molecular properties.

How Pauling.AI Compares to Alternatives

• Unlike point solutions such as AlphaFold or Boltz, Pauling.AI delivers a complete end-to-end workflow rather than a single-purpose model requiring manual integration.
• Unlike complex tools such as Schrödinger, no computational chemistry expertise or weeks of learning are required — results are available in hours to days.
• Unlike CRO services, the process is fully transparent with documented methodology, and there are no human bottlenecks or resource constraints limiting throughput.
• Pauling.AI integrates the latest AI models automatically, whereas alternatives require manual setup or complex configuration.

Pauling.AI is a patent-pending platform supported by leading organizations in the life sciences and AI space. It is trusted by pioneering researchers looking to accelerate their drug discovery programs and unlock scientific breakthroughs through full in silico automation.